Therapy1

[WP-20-2] Frequent, significant responses are observed with 177Lu-PSMA treatment in metastatic castration resistant prostate cancer, which associate to improved survival

Jukka Kemppainen^1,2、Aki Kangasmäki ¹、Simona Malaspina^2,3、Kalevi Kairemo¹、Juha Kononen¹、Timo Joensuu¹ (1.Docrates Cancer Center、2.University of Turku、3.Turku University Hospital)